>>Every analyst, so far, is praising the deal. This is like a review of a movie. The critics rave yet no one is seeing it. I think this is a case of wall st just doesn't understand biotechs that well ro that they just don't like LGNd. Case in point, CORR. Once they came out with the postive clinical on their drug, the stock took off. I know they are expecting fda approval, but is CORR anywhere near the company lgnd is?<<
We don't need praise from the analysts, we need some new buy recs. If the Street doesn't understand it, they will be hesitant to buy it. These new pr guys should be making it comprehensible to the Street, but they probably don't understand it themselves. (:>)
As for CORR, they took a big dive a while ago, because one of their clinicals looked bad. Situation is different with LGND. All their clinicals have been good, but the indications for clinicals so far are fairly small markets. The lung cancer market for Targretin will be a big one, however. If the tobacco companies were smart, they would include a few Targretin oral capsules with each pack of cigarettes. (:>) |
